Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Inflammation Therapeutics
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TSLP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Ligand) | Human / Cyno / Mouse TSLP Recombinant Protein. HEK293 Expressed, High Purity (>95%), Endotoxin <1 EU/µg. Sequence verified for cross-species toxicology studies. | View TSLP Products |
| Receptor Complex | TSLPR (CRLF2) ECD-Fc Fusion Protein. Sequence verified. For binding competition and blocking assays. | View TSLPR Products |
| Co-receptor | IL-7 Receptor α (IL7R / CD127) ECD-Fc Protein. Required for heterodimeric receptor complex formation assays. | View IL7R Products |
| Benchmark Ab | Anti-TSLP (Tezepelumab Biosimilar). Sequence-verified positive control for neutralization and binding assays. | View TSLP Products |
| Validator | TSLP siRNA Set. For target specificity and knockdown verification in cellular models. | View TSLP Products |
| Gene Delivery | TSLP Promise-ORF / Lentivirus. Full-length ORF for stable overexpression cell lines. | View TSLP Products |
| Related Target (Th2) | IL-13. Downstream Th2 cytokine; key combination therapy candidate. | View IL13 Products |
| Related Target (Shared receptor) | IL-4Rα. Shared Th2 pathway receptor; anchor for dual-targeting strategies. | View IL4R Products |
| Related Target (Alarmin synergy) | IL-33. Synergistic epithelial alarmin; core partner for bispecific antibodies. | View IL33 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species binding assessment (Human / Cyno / Mouse) | Ortholog panel (Human/Mouse/Cyno) with >95% purity; sequence verified for epitope conservation. |
| TSLP–TSLPR interaction blocking | High-affinity TSLPR (CRLF2) ECD-Fc available for SPR / BLI competition assays. |
| High-concentration formulation stability | Low-endotoxin (<1 EU/µg), aggregate-free protein standards for sub-Q developability simulation. |
| Cellular signaling inhibition | Lentivirus particles for TSLPR / IL7R stable cell line construction (Ba/F3 transduction). |
| Specificity control (off-target check) | IL-7, IL-2, IL-4, IL-15 protein controls; homolog panel verified by Mass Spec to exclude cross-reactivity. |
Live TSLP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TSLP therapeutics is intensifying. First-generation anti-TSLP monoclonal antibodies, notably AstraZeneca and Amgen's Tezepelumab (Tezspire), have reshaped the severe asthma landscape by establishing a broad, eosinophil-independent efficacy profile. The next wave of R&D is rapidly expanding into atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). Competitive differentiation is increasingly driven by novel routes of administration (inhaled biologics such as Novartis/CSL's CSJ117), bispecific antibodies targeting TSLP together with IL-13 or IL-33, and small-molecule antagonists of TSLPR. The industry is focusing on half-life extension, patient stratification (pediatric, non-eosinophilic), and combination strategies that block both upstream alarmins and downstream Th2 cytokines to overcome compensatory pathway activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-TSLP mAb | AstraZeneca / Amgen (Tezepelumab), Novartis/CSL (CSJ117, inhaled) | Severe asthma, AD, CRSwNP, COPD | Neutralization assay vs. WT/mutant TSLP; cross-species binding (need high-purity ortholog panel) |
| TSLPR Antagonist (Small Molecule) | Emerging biotech pipelines | Atopic dermatitis, asthma | Receptor–ligand competition assay (need TSLPR ECD-Fc and TSLP protein pair) |
| Inhaled Biologics (Fab / Nanobody) | Novartis/CSL, Upstream Bio | Asthma, COPD | Stability at pulmonary delivery conditions; pH-dependent binding kinetics |
| Bispecific (TSLP/IL-13, TSLP/IL-33) | Sanofi, Regeneron, early pipeline programs | Severe asthma, type 2 inflammatory diseases | Dual-target binding validation; heterodimer Fc detection (need cross-reactive orthologs and benchmark controls) |